AlphaValue Corporate Services
This research has been commissioned and paid for by the company and is deemed to constitute an acceptable minor non-monetary benefit as defined in MiFID II

Crossject

CR
Bloomberg   ALCJ FP
Supergenerics  /  France  Web Site   |   Investors Relation
Things get going
Target
Upside 468%
Price (€) 2.02
Market Cap (€M) 73.6
Perf. 1W: -8.41%
Perf. 1M: -39.1%
Perf. 3M: -65.2%
Perf Ytd: -59.5%
10 day relative perf. to stoxx600: -33.5%
20 day relative perf. to stoxx600: -38.7%
EPS change05/09/2022

Adjusting our forecasts to the new number of shares

Change in EPS2022 : € -0.23 vs -0.26ns
2023 : € -0.25 vs -0.31ns

We have adjusted our numbers to the current number of shares (after the latest exercise of subscription rights) which now stands at 34.83m as of August 2022. As a result, the loss per share for FY22/23 decreases.



Change in NAV€ 12.3 vs 13.3-7.88%

We have adjusted our numbers to the current number of shares (after the exercise of subscription rights) which now stands at 34.83m as of August 2022.



Change in DCF€ 13.3 vs 14.6-9.05%

We have adjusted our numbers to the current number of shares (after the latest exercise of subscription rights) which now stands at 34.83m as of August 2022.



Updates
.